Letrozole SanoSwiss 2

DRUG2 trials

Sponsors

Puma Biotechnology Inc., Pfizer Inc.

Conditions

HER2-NEGATIVE BREAST CANCERHORMONE RECEPTOR-POSITIVEHormone receptor positive (HR+)human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)

Phase 2

A Phase 2 study of alisertib in combination with endocrine therapy in patients with HR+, HER2-negative recurrent or metastatic breast cancer

RecruitingCTIS2024-511497-79-00

Puma Biotechnology Inc.Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)

Start: 2024-12-30Target: 54Updated: 2025-12-23

C4391025_AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER IN THE NEOADJUVANT SETTING

CompletedCTIS2024-512848-30-00

Pfizer Inc.HER2-NEGATIVE BREAST CANCER, HORMONE RECEPTOR-POSITIVE

Start: 2024-11-12End: 2025-07-10Target: 76Updated: 2025-08-26